Lightstone Ventures

Type

Venture Capital

Status

Active

Location

Menlo Park, United States

Total investments

67

Average round size

49M

Portfolio companies

37

Rounds per year

5.58

Lead investments

9

Follow on index

0.45

Exits

9

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaWearables

Summary

In 2012 was created Lightstone Ventures, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Menlo Park.

We also calculated 5 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight Earlens Corporation, Bold Penguin, Locana. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical Device. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Lightstone Ventures, startups are often financed by New Enterprise Associates, Advanced Technology Ventures, Vertex Ventures HC. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures HC, Atlas Venture, Windham Venture Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Vertex Ventures HC, Windham Venture Partners.

Speaking about the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lightstone Ventures performs on 13 percentage points less the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. The higher amount of exits for fund were in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 375000000
Fund raised date
2021-09-24

Analytics

Total investments
67
Lead investments
9
Exits
9
Rounds per year
5.58
Follow on index
0.45
Investments by industry
  • Biotechnology (50)
  • Health Care (41)
  • Therapeutics (29)
  • Medical (22)
  • Medical Device (19)
  • Show 26 more
Investments by region
  • United States (51)
  • Ireland (8)
  • United Kingdom (2)
  • The Netherlands (1)
  • France (1)
  • Show 3 more
Peak activity year
2020
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
81M
Group Appearance index
0.99
Avg. company exit year
7
Avg. multiplicator
6.40
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Alchemab Therapeutics 15 Apr 2021 Biotechnology, Medical, Pharmaceutical Early Stage Venture 82M England, London, United Kingdom
Amber Therapeutics 10 Jun 2024 Biotechnology, Therapeutics Early Stage Venture 109M England, London, United Kingdom

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.